625446-22-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-fluoroacetophenone is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure allows for the creation of diverse compounds with potential therapeutic applications, making it a valuable component in drug development.
Used in Dye Industry:
In the dye industry, 4-Bromo-2-fluoroacetophenone is utilized as a starting material for the synthesis of different types of dyes. Its chemical properties enable the production of dyes with specific color characteristics and stability, catering to various industrial needs.
Used in Chemical Research:
4-Bromo-2-fluoroacetophenone is employed as a research compound in the field of organic chemistry. Its reactivity and structural features make it an interesting subject for studying chemical reactions and exploring new synthetic pathways.
Used in Specialty Chemicals Production:
4-Bromo-2-fluoroacetophenone is used as a starting material in the preparation of other specialized chemicals. Its versatility in chemical transformations allows for the development of unique compounds with specific applications in various industries.

InChI:InChI=1/C8H6BrFO/c1-5(11)7-3-2-6(9)4-8(7)10/h2-4H,1H3

Upstream product

• 75-16-1 methylmagnesium bromide 
• 801303-33-3 4-bromo-2-fluoro-N-methoxy-N-methylbenzamide 
• 302912-33-0 4-bromo-1-ethynyl-2-fluorobenzene 
• 99-90-1 para-bromoacetophenone 
• 74-88-4 methyl iodide 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 676-58-4 methylmagnesium chloride 
• 353282-88-9 1-(4-bromo-2-fluorophenyl)ethanol 

Downstream Products

• 1000381-62-3 N-[5-(4-acetyl-3-fluoro-phenyl)-4-methyl-thiazol-2-yl]-acetamide 
• 869569-77-7 1-(4-bromo-2-fluorophenyl)-2-bromo-1-ethanone 
• 947685-09-8 1-(4-bromo-2-fluorophenyl)ethanone hydrazone 
• 1007346-31-7 C₁₅H₁₁BrFN₃ 
• 7746-27-2 6-bromo-3-methyl-1 H-indazole 
• 1345404-73-0 3-methyl-1-phenyl-1H-indazol-6-ylamine hydrochloride 
• 1372148-66-7 C₁₂H₁₃BrFNO 
• 1372148-79-2 C₂₀H₁₄BrF₂NO₃ 
• 1372148-82-7 C₁₆H₈BrF₂NO₃ 
• 1372148-84-9 C₁₅H₉BrF₂N₂O 
• 1372148-69-0 C₁₆H₁₁BrF₃NO 
• 1315179-98-6 7-bromo-1-(2, 4-difluorophenyl)-2-methyl-1, 4-dihydro-4-oxoquinoline 
• 1372148-63-4 C₁₆H₈BrF₂NO₂ 
• 1372148-71-4 C₁₆H₁₀BrF₂NO₂ 

Relevant academic research and scientific papers

Pd-Catalysed direct C(sp2)-H fluorination of aromatic ketones: Concise access to anacetrapib

The Pd-cataylsed direct ortho-C(sp2)-H fluorination of aromatic ketones has been developed for the first time. The reaction features good regioselectivity and simple operations, constituting an alternative shortcut to access fluorinated ketones. A concise synthesis of anacetrapib has also been achieved by using late-stage C-H fluorination as a key step.

Dual-Metal N-Heterocyclic Carbene Complex (M = Au and Pd)-Functionalized UiO-67 MOF for Alkyne Hydration-Suzuki Coupling Tandem Reaction

Metal N-heterocyclic carbene complexes (NHC-M) have been recognized as an important class of organometallic catalysts. Herein, we demonstrate that different NHC-M (M = Au and Pd) species can be simultaneously introduced into a single metal organic framework (MOF) by direct assembly of NHC-M-decorated ligands and metal ions under solvothermal conditions. The obtained UiO-67-Au/Pd-NHBC MOF with different organometallic NHC-M species can be a highly reusable dual catalyst to sequentially promote alkyne hydration-Suzuki coupling reaction. The potential utility of this strategy is highlighted by the preparation of many more new multicatalysts of this type for various organic transformations in a sequential way.

Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mG

This work describes the discovery and characterization of novel 6-(1H-pyrazolo[4,3-b]pyridin-3-yl)amino-benzo[d]isothiazole-3-carboxamides as mGlu4 PAMs. This scaffold provides improved metabolic clearance and CYP1A2 profiles compared to previo

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

HETEROCYCLIC COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS FOR THE TREATMENT OF HYPERPARATHYROIDISM, CHRONIC RENAL FAILURE AND CHRONIC KIDNEY DISEASE

The invention relates to heterocyclic compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their pharmaceutical compositions for use in medicine for the treatment of diseases or disorders associated with the modulation of calcium sensing receptor modulators (CaSR), like e.g. hyperparathyroidism, chronic renal failure and chronic kidney disease and their complications.

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocycle derivative having a superior amyloid β production inhibitory activity and/or a superior γ-secretase modulation activity, and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocycle derivative having a superior amyloid β production inhibitory activity and use thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS

JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS

The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.

NOVEL KINASE MODULATORS

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.